<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03550235</url>
  </required_header>
  <id_info>
    <org_study_id>2017-A01621-52</org_study_id>
    <nct_id>NCT03550235</nct_id>
  </id_info>
  <brief_title>Exploration of Dyspnea at Non-high Brain Natriuretic Peptide (BNP)</brief_title>
  <acronym>NEON HFpEF</acronym>
  <official_title>Exploration of Dyspnea at Non-high BNP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with unexplained stress dyspnea ( ≥ stage 2 NYHA), no significant underlying lung
      disease, with an ejection fraction &gt; 50%, normal resting filling pressures, NTproBNP &lt; 220
      pg/ml in &lt; 75 years, and &lt; 450 pg/ml in ≥ 75 years will be studied with stress
      echocardiography and cardiometabolic stress test (VO2). These patients may have abnormal
      adaptation during exercise, suggesting that chronic symptoms may be related to a heart
      failure with preserved ejection fraction (HFPEF). More accurate and earlier diagnosis of
      HFPEF using stress echocardiography and VO2 may better manage stress dyspnea in patients and
      prevent progression of HFPEF.

      A clinical assessment will be offered to people with unexplained stress dyspnea. The
      procedures and products used in this study are usually used as part of HFpEF's diagnostic
      strategy. During this assessment, carried out on an outpatient basis, an anamnesis
      collection, a cardiovascular clinical examination, an evaluation of dyspnea by the NYHA
      functional class and by 2 questionnaires, an electrocardiogram will be carried out, a
      6-minute walk test, a biological blood test, a trans thoracic rest and stress cardiac
      ultrasound, respiratory functional tests (with diffusion capacity of lung for carbon monoxide
      (DLCO) and blood gas), and a metabolic stress test. A follow-up at 1 and 2 years is planned
      (visit, sampling and resting echocardiography).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2018</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Occurence of HFpEF</measure>
    <time_frame>during the 2 years of follow-up</time_frame>
    <description>HFpEF diagnosis will be made in attendance of following symptoms:
heart failure
NTproBNP&gt;125pg/ml
preservation of ejection fraction with Left Ventricular Ejection Fraction (LVEF)&gt;50%
structural heart disease with expansion of left ventricular mass (VM) (men: VM≥115 g/m² or women ≥ 95 g/m² and an E/e' ratio≥13</description>
  </primary_outcome>
  <primary_outcome>
    <measure>dyspnea on exertion</measure>
    <time_frame>during the 2 years of follow-up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>NTproBNP levels at rest</measure>
    <time_frame>during the 2 years of follow-up</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Heart Failure With Preserved Ejection Fraction</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All referred patients for unexplained dyspnea that must be assessed
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient over 40 years of age, and under 80 years of age with unexplained effort
             dyspnea, able to pedal.

          -  Echocardiographic ejection fraction &gt; 50%

          -  NTproBNP &lt; 220 pg/ml in &lt; 75 years, and &lt; 450 pg/ml in ≥ 75 years

        Exclusion Criteria:

          -  Patient with coronary, valve, hypertrophic, hypertensive, infiltrative, constrictive,
             or rhythmic, significant and/or progressive heart disease.

        BMI &gt; 35 kg/m².

          -  Unstable patient (systolic blood pressure &lt; 90 mmHg, resting pulse &gt; 100 BPM) or
             clinically congested (edema of the lower limbs, crackling in the lungs).

          -  Patient with Pulmonary function testing (EFR) showing significant respiratory disease
             (FEV1/ vital capacity (CV) max &lt; 0.7, total lung capacities (CPT)&lt; LIN)

          -  Chronic renal failure with creatinine clearance &lt; 30 ml/min (MDRD) or dialysis

          -  Patient with anemia (Hb &lt; 12 g/dl)

          -  Patient with hypo or hyperthyroidism on thyreostimulating hormone (TSH) value

          -  Patient under justice safeguard measure or guardianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanuelle BERTHELOT, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>AP-HP Hôpital Bicêtre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emmanuelle BERTHELOT, Dr</last_name>
    <phone>33145213735</phone>
    <email>emmanuelle.berthelot@aphp.Fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hopital Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuelle Berthelot, Dr</last_name>
      <email>emmanuelle.berthelot@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Polyclinique de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barnabas GELLEN, Dr</last_name>
      <email>barnabas.gellen.cardio@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Erwan Donal, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CCM RANGUEIL - LARREY CHU toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059 Toulouse Cedex 9</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Lairez, Pr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>April 27, 2018</study_first_submitted>
  <study_first_submitted_qc>May 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2018</study_first_posted>
  <last_update_submitted>December 16, 2019</last_update_submitted>
  <last_update_submitted_qc>December 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>dyspnea</keyword>
  <keyword>stress test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspnea</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

